MedTrace Logo

Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis

NCT00078793 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2013-05-14

No results posted yet for this study

Summary

This study will evaluate long-term safety of etanercept with or without other DMARDs in children with polyarticular course or systemic juvenile rheumatoid arthritis (JRA) compared to a cohort of subjects with polyarticular or systemic JRA receiving methotrexate with or without other DMARDs.

Conditions

  • Juvenile Rheumatoid Arthritis

Interventions

DRUG

Enbrel®

Etanercept alone, etanercept plus methotrexate or other DMARDs

Sponsors & Collaborators

  • Immunex Corporation

    collaborator INDUSTRY

  • Amgen

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-06-30
Primary Completion
2008-01-31
Completion
2008-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00078793 on ClinicalTrials.gov